首页> 外文期刊>Basic Sciences of Medicine >Effect of Sitagliptin (Januvia) on the Thyroid Gland of Adult Male Albino Rats in an Experimental Model of Type II Diabetes Mellitus - (Biochemical, Histological and Immunohistochemical Studies)
【24h】

Effect of Sitagliptin (Januvia) on the Thyroid Gland of Adult Male Albino Rats in an Experimental Model of Type II Diabetes Mellitus - (Biochemical, Histological and Immunohistochemical Studies)

机译:西他列汀(Januvia)对II型糖尿病实验模型对成年雄性白化大鼠甲状腺的影响-(生化,组织学和免疫组化研究)

获取原文
       

摘要

Type II diabetes mellitus is a major global health problem and there is ongoing research for new treatments to manage the disease. The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological response to the incretin peptide, GLP- 1, Sitglaptin, is a DPP- IV inhibitor and through its effect on receptor GLP-1 seems to have much wider effects on the function and survival of cells that express its receptor. Also, inhibitors of dipeptidyl peptidase-IV (DPP-IV) are a novel class of anti-diabetes drugs; inhibiting the breakdown of incretins, they increase their biological availability and thus decrease blood glucose level. In addition to regulating glucose homeostasis, DPP-IV has many diverse functions, such as modulating cell growth, cellular differentiation and transformation and it can disturb the immune function. Effect of DPP-IV inhibitors in humans are scarce, it has a risk of infections and the tendency towards a higher incidence of some tumors which fall in line with experimental evidence suggesting the possibility of their adverse immunological and oncological effects. Aim of work : This study was set to evaluate the possible side effects of Sitagliptin on the thyroid gland of the adult male rats after induction of diabetes mellitus II by Alloxan. Material and Methods: Thirty adult male albino rats were divided into three equal groups: control group, diabetic non treated group and diabetic rats treated with therapeutic dose of Sitagliptin (100 mg/kg/day) for eight weeks. At the end of the experimental period, the hormones of thyroid function, calcitonin in addition to histological, ultra structural and immune-cytochemical examinations of the thyroid tissue calcitonin and caspase 3. Also, evaluation of the oxidative markers were carried. The results: showed that treatment with Sitagliptin caused significant increase in free T3 and calcitonin level (P<0.001) with significant increase of oxidative markers (P<0.001). Histological examination showed evidence of stratification and focal hyperplasia of the follicular cells with strong PAS reaction in addition to engorgement of Golgi system and dilatation of the rough endoplasmic reticulum with presence of multiple secondary lysosomes. Immunohistochemical results showed significant increase (P<0.001) of calcitonin immunopositive expression of thyroid C-cells which appeared stronger than normal, in addition to marked significant increase (P<0.001) in area percent of caspase-3 immunopositive cells which appeared as massive dense brown cytoplasmic deposits.Conclusion s :Sitagliptin administration induced changes in the thyroid tissues leading to quantitative and qualitative alterations in the hormonal levels and enhancement of apoptosis.
机译:II型糖尿病是一个主要的全球性健康问题,目前正在进行有关治疗该病的新疗法的研究。胰高血糖素样肽-1受体(GLP-1R)控制对肠降血糖素肽GLP-1(Sitglaptin)的生理反应,是一种DPP-IV抑制剂,并且通过其对受体GLP-1的作用似乎对表达其受体的细胞的功能和存活。同样,二肽基肽酶-IV(DPP-IV)的抑制剂是一类新型的抗糖尿病药物。抑制肠降血糖素的分解,它们增加了生物利用度,从而降低了血糖水平。除了调节葡萄糖稳态之外,DPP-IV还具有许多不同的功能,例如调节细胞生长,细胞分化和转化,并且可以干扰免疫功能。 DPP-IV抑制剂在人类中的作用很少,有感染的危险,某些肿瘤的发生率更高,这与实验证据相符,表明它们可能具有不利的免疫学和肿瘤学作用。工作目的:这项研究旨在评估西格列汀对四氧嘧啶诱导的II型糖尿病后成年雄性大鼠甲状腺的可能副作用。材料和方法:将三十只成年雄性白化病大鼠分为三组,分别为对照组,糖尿病非治疗组和用西他列汀(100 mg / kg /天)治疗剂量治疗的糖尿病大鼠。八个星期。在实验期结束时,除了组织学,甲状腺组织降钙素和胱天蛋白酶3的组织学,超微结构和免疫细胞化学检查外,还对甲状腺功能激素,降钙素进行了检测。此外,还进行了氧化标志物的评估。结果:显示西他列汀治疗导致游离T3和降钙素水平显着增加(P <0.001),而氧化标记显着增加(P <0.001)。组织学检查显示,除了高尔基体系统充血和粗糙的内质网扩张并伴有多个次级溶酶体外,PAS反应强烈还可以使卵泡细胞分层和局灶性增生。免疫组织化学结果显示,甲状腺C细胞的降钙素免疫阳性表达显着增加(P <0.001),似乎比正常情况强;此外,呈大量密集的caspase-3免疫阳性细胞的面积百分比显着增加(P <0.001)。结论:西格列汀给药可引起甲状腺组织变化,导致激素水平发生定量和定性变化,并增强细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号